Corrigendum to "Utilisation trend of long-acting insulin analogues including biosimilars across Europe: findings and implications"

Godman, Brian and Wladysiuk, Magdalene and McTaggart, Stuart and Kurdi, Amanj and Allocati, Eleonora and Jakovljevic, Mihajlo and Kalemeera, Francis and Hoxha, Iris and Nachtnebel, Anna and Sauermann, Robert and Hinteregger, Manfred and Marković-Peković, Vanda and Tubic, Biljana and Petrova, Guenka and Tachkov, Konstantin and Slabý, Juraj and Nejezchlebova, Radka and Krulichová, Iva Selke and Laius, Ott and Selke, Gisbert and Langner, Irene and Harsanyi, András and Inotai, András and Jakupi, Arianit and Henkuzens, Svens and Garuolienė, Kristina and Gulbinovič, Jolanta and Bonanno, Patricia Vella and Rutkowski, Jakub and Ingeberg, Skule and Melien, Øyvind and Mardare, Ileana and Fürst, Jurij and MacBride-Stewart, Sean and Holmes, Carol and Pontes, Caridad and Zara, Corinne and Pedrola, Marta Turu and Hoffmann, Mikael and Kourafalos, Vasileios and Pisana, Alice and Banzi, Rita and Campbell, Stephen and Wettermark, Bjorn (2023) Corrigendum to "Utilisation trend of long-acting insulin analogues including biosimilars across Europe: findings and implications". BioMed Research International, 2023. 9757348. ISSN 2314-6133 (https://doi.org/10.1155/2023/9757348)

[thumbnail of Godman-etal-BMRI-2023-Corrigendum-to-Utilisation-trend-of-long-acting-insulin]
Preview
 Text. Filename: Godman_etal_BMRI_2023_Corrigendum_to_Utilisation_trend_of_long_acting_insulin.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (554kB)| Preview

Abstract

In the article titled "Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications" [1], the captions of Figures 3 and 4 were incorrect. The corrected captions for Figures 3 and 4 appear below.

CORE (COnnecting REpositories)